Summit Therapeutics Inc. Amortization of Intangible Assets
Summit Therapeutics Inc. (SMMT) reported Amortization of Intangible Assets of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2025-02-24
- Summit Therapeutics Inc. amortization of intangible assets for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. amortization of intangible assets for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. amortization of intangible assets for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. amortization of intangible assets for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. amortization of intangible assets for fiscal 2024 was $0.00.
- Summit Therapeutics Inc. amortization of intangible assets for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Summit Therapeutics Inc. amortization of intangible assets for fiscal 2022 was $914.00K, a 10.13% decline from fiscal 2021.
- Summit Therapeutics Inc. amortization of intangible assets for fiscal 2021 was $1.02M, a 18.64% decline from fiscal 2020.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 11 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-24 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $0.00 derived: sum of 2 quarters · filed 2025-02-24 | $0.00 derived: sum of 3 quarters · filed 2025-02-24 | $0.00 10-K · filed 2025-02-24 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | $217.00K derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | $217.00K derived: sum of 3 quarters · filed 2025-02-24 | $434.00K derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | $217.00K derived: sum of 2 quarters · filed 2025-02-24 | $434.00K derived: sum of 3 quarters · filed 2025-02-24 | $666.00K derived: sum of 4 quarters · filed 2025-02-24 | |
| 2022-12-31 | $217.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $434.00K derived: sum of 2 quarters · filed 2025-02-24 | $666.00K derived: sum of 3 quarters · filed 2025-02-24 | $914.00K 10-K · filed 2025-02-24 | |
| 2022-09-30 | $217.00K 10-Q · filed 2023-11-07 | $449.00K derived: sum of 2 quarters · filed 2023-11-07 | $697.00K 10-Q · filed 2023-11-07 | $946.00K derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $232.00K 10-Q · filed 2023-08-09 | $480.00K 10-Q · filed 2023-08-09 | $729.00K derived: sum of 3 quarters · filed 2023-08-09 | $985.00K derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | $248.00K 10-Q · filed 2023-05-11 | $497.00K derived: sum of 2 quarters · filed 2023-05-11 | $753.00K derived: sum of 3 quarters · filed 2023-05-11 | $1.01M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $249.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $505.00K derived: sum of 2 quarters · filed 2023-03-09 | $762.00K derived: sum of 3 quarters · filed 2023-03-09 | $1.02M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $256.00K 10-Q · filed 2022-11-09 | $513.00K derived: sum of 2 quarters · filed 2022-11-09 | $768.00K 10-Q · filed 2022-11-09 | $1.19M derived: sum of 4 quarters · filed 2022-12-21 | |
| 2021-06-30 | $257.00K 10-Q · filed 2022-08-11 | $512.00K 10-Q · filed 2022-08-11 | $935.00K derived: sum of 3 quarters · filed 2022-12-21 | $1.24M derived: sum of 4 quarters · filed 2022-12-21 | |
| 2021-03-31 | $255.00K 10-Q · filed 2022-05-11 | $678.00K derived: sum of 2 quarters · filed 2022-12-21 | $983.00K derived: sum of 3 quarters · filed 2022-12-21 | $1.24M derived: sum of 4 quarters · filed 2022-12-21 | |
| 2020-12-31 | $423.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | $728.00K derived: sum of 2 quarters · filed 2022-12-21 | $984.00K derived: sum of 3 quarters · filed 2022-12-21 | $1.25M 10-K/A · filed 2022-12-21 | |
| 2020-09-30 | $305.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $561.00K derived: sum of 2 quarters · filed 2021-11-15 | $827.00K 10-Q · filed 2021-11-15 | $1.04M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | $256.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $522.00K 10-Q · filed 2021-08-12 | $731.00K derived: sum of 3 quarters · filed 2021-08-12 | $987.00K derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $266.00K 10-Q · filed 2021-05-17 | $475.00K derived: sum of 2 quarters · filed 2021-05-17 | $731.00K derived: sum of 3 quarters · filed 2021-05-17 | ||
| 2019-12-31 | $209.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2020-11-16 | $465.00K derived: sum of 2 quarters · filed 2020-11-16 | $970.00K 10-K · filed 2021-03-31 | $1.00M 10-Q · filed 2020-11-16 | |
| 2019-09-30 | $256.00K derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16 | $791.00K 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | $535.00K 8-K · filed 2020-09-29 | ||||
| 2019-01-31 | $1.10M 10-K · filed 2021-03-31 | ||||
| 2018-01-31 | $137.00K 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |